Información sobre riesgo, prevención, detección, síntomas, diagnosis, tratamiento y apoyo para el cáncer.
Información sobre el tratamiento del cáncer incluyendo quirúrgica, quimioterapia, radioterapia, estudios clínicos, terapia con protón, medicina complementaria avanzadas.
OncoLink se complace en ofrecer una amplia lista de lista completa de los agentes quimioterapéuticos más comúnmente usados??. Esta guía de referencia incluye información sobre la forma en que cada fármaco se administra, cómo funcionan, y los pacientes los efectos secundarios comunes pueden experimentar.
Maneras que los pacientes de cáncer y las personas que le cuidan puedan enfrentar el cáncer, los efectos secundarios, nutrición, cuestiones en general sobre el apoyo para el cáncer, duelo/decisiones sobre el termino de vida, y experiencias compartidas por sobrevivientes.
Reviewer: S. Jack Wei, MD
University of Pennsylvania School of Medicine
Ultima Vez Modificado: 15 de mayo del 2005
Presenter: A.B. Sandler
Presenter's Affiliation: Easteran Cooperative Oncology Group
Type of Session: Plenary
Materials and Methods
This study shows significant improvement in OS, PFS, and RR with the addition of bevacizumab to standard chemotherapy in treatment-naive patients with non-squamous NSCLC. This study follows positive studies in colorectal cancer and breast cancer that showed an overall survival benefit with the addition of bevacizumab to standard chemotherapy in advanced disease. Interestingly, compared to these other trials, there appears to be a higher rate of severe, life-threatening toxicity in this trial. The 4.5% rate of grade 3-5 toxicity was consistent with the 4% rate of life-threatening hemorrhage seen in the phase II trial with bevacuzimab in patients with non-squamous histology. It is concerning that 8 patients died of treatment-related complications including 5 patients with severe hemorrhage in this study. Clearly, bevacizumab should be used with caution in these patients. Nevertheless, despite the higher rate of treatment related deaths in the PCB arm of this study, there was a survival advantage to the use of bevacizumab, and it is reasonable to use bevacizumab in patients with advanced NSCLC of non-squamous histology with no history of coagulopathies or hemoptysis.
It should be noted that although the benefit of bevacizumab was limited to males, the reason for this is unclear. It is possible that other causes, such as use of secondary therapy with tyrosine kinase inhibitors (which have been found to preferentially benefit women), account for these differences. Despite this interesting finding, it is not consistent with other studies of bevacuzimab which have not shown a preferential benefit in males, and in fact is contradictory to the pattern of NSCLC in general where women have improved outcomes compared to men. Bevacuzimab remains an interesting option ifor all patients n the growing list of targeted therapies that are being used in NSCLC.
Ms. Gambino talks about the complexity of cancer care and the need for patients and families to have help in navigating from diagnosis and treatment decisions to survivorship. Read more.
Endocrine System Cancers
Head and Neck Cancers
Urinary Tract Cancers
Bone Marrow Transplants
General Treatment Concerns
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
Cancer Resource List
Resources for Young Adults